MA33974B1 - Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek - Google Patents

Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Info

Publication number
MA33974B1
MA33974B1 MA34821A MA34821A MA33974B1 MA 33974 B1 MA33974 B1 MA 33974B1 MA 34821 A MA34821 A MA 34821A MA 34821 A MA34821 A MA 34821A MA 33974 B1 MA33974 B1 MA 33974B1
Authority
MA
Morocco
Prior art keywords
inhibitor
combinations
pi3k
mek
kinase inhibitor
Prior art date
Application number
MA34821A
Other languages
Arabic (ar)
English (en)
Inventor
Marcia Belvin
Iris T Chan
Lori Friedman
Klause P Hoeflich
John Prescott
Jeffrey Wallin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33974(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33974B1 publication Critical patent/MA33974B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des procédés de traitement d'un patient présentant des tumeurs solides localement avancées ou métastasiques par une combinaison d'un inhibiteur de phosphatidylinositol 3-kinase (pi 3-kinase ou pi3k) et un inhibiteur de kinase de kinase de protéine activée par le mitogène.
MA34821A 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek MA33974B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (fr) 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Publications (1)

Publication Number Publication Date
MA33974B1 true MA33974B1 (fr) 2013-02-01

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34821A MA33974B1 (fr) 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Country Status (24)

Country Link
US (1) US20110086837A1 (fr)
EP (1) EP2488178B1 (fr)
JP (2) JP2013507415A (fr)
KR (1) KR101489045B1 (fr)
CN (1) CN102740851B (fr)
AR (1) AR078588A1 (fr)
AU (1) AU2010314287A1 (fr)
BR (1) BR112012008483A2 (fr)
CA (1) CA2776944A1 (fr)
CL (1) CL2012000913A1 (fr)
CO (1) CO6531463A2 (fr)
CR (1) CR20120173A (fr)
EC (1) ECSP12011865A (fr)
ES (1) ES2609767T3 (fr)
IL (1) IL219105A0 (fr)
MA (1) MA33974B1 (fr)
MX (1) MX345155B (fr)
NZ (1) NZ599939A (fr)
PE (1) PE20121816A1 (fr)
PH (1) PH12012500709A1 (fr)
RU (1) RU2563193C2 (fr)
TW (1) TWI428336B (fr)
WO (1) WO2011054620A1 (fr)
ZA (1) ZA201202618B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
PT3111938T (pt) 2011-04-01 2019-07-10 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
JP6062442B2 (ja) 2011-10-13 2017-01-18 ジェネンテック， インコーポレイテッド 薬剤誘発性低酸症の治療
KR20140097205A (ko) * 2011-10-28 2014-08-06 제넨테크, 인크. 흑색종을 치료하는 치료 조합물 및 방법
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
CN104334192A (zh) * 2012-04-06 2015-02-04 赛诺菲 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
WO2013157648A1 (fr) * 2012-04-19 2013-10-24 国立大学法人九州大学 Composition pharmaceutique
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014022680A1 (fr) 2012-08-02 2014-02-06 Genentech, Inc. Anticorps et immunoconjugués anti-etbr
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014152358A2 (fr) * 2013-03-14 2014-09-25 Genentech, Inc. Combinaisons d'un composé inhibiteur de mek avec un composé inhibiteur de her3/egfr et procédés d'utilisation
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
EP3193902A4 (fr) * 2014-09-11 2018-03-28 The Regents of The University of California Inhibiteurs de mtorc1
EP3849554B1 (fr) 2018-09-11 2025-01-29 Curis, Inc. Polythérapie avec un inhibiteur de phosphoinositide 3-kinase ayant une fraction de liaison au zinc
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (fr) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (fr) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
AU685933B2 (en) * 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU7349801A (en) * 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. ｐ38 억제제 및 그의 사용 방법
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
KR101533461B1 (ko) * 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
CA2658725A1 (fr) * 2006-08-16 2008-02-21 Exelixis, Inc. Procedes d'utilisation de modulateurs pi3k etmek
PE20081679A1 (es) * 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
BRPI0816769A2 (pt) * 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.

Also Published As

Publication number Publication date
US20110086837A1 (en) 2011-04-14
KR20120064132A (ko) 2012-06-18
PH12012500709A1 (en) 2012-10-29
CO6531463A2 (es) 2012-09-28
EP2488178B1 (fr) 2016-11-16
KR101489045B1 (ko) 2015-02-02
CR20120173A (es) 2012-07-04
TW201118082A (en) 2011-06-01
BR112012008483A2 (pt) 2019-09-24
JP5745678B2 (ja) 2015-07-08
MX345155B (es) 2017-01-18
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
JP2013507415A (ja) 2013-03-04
IL219105A0 (en) 2012-06-28
AR078588A1 (es) 2011-11-16
CN102740851A (zh) 2012-10-17
AU2010314287A1 (en) 2012-05-03
WO2011054620A1 (fr) 2011-05-12
ECSP12011865A (es) 2012-06-29
ES2609767T3 (es) 2017-04-24
CN102740851B (zh) 2013-12-18
CA2776944A1 (fr) 2011-05-12
AU2010314287A2 (en) 2012-07-12
JP2015038110A (ja) 2015-02-26
EP2488178A1 (fr) 2012-08-22
NZ599939A (en) 2014-02-28
ZA201202618B (en) 2014-10-29
PE20121816A1 (es) 2013-01-02
RU2012118974A (ru) 2013-11-20
HK1175125A1 (en) 2013-06-28
CL2012000913A1 (es) 2012-09-14
TWI428336B (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
MX345155B (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2010003013A (es) Inhibicion de angiogenesis.
NZ588033A (en) Methods of treating a mif-mediated disorder
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
CR20120653A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
BR112014004577A2 (pt) inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.